| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | 0.25 | 3e-16 |
| mRNA | nelarabine | CTRPv2 | pan-cancer | AAC | 0.33 | 3e-16 |
| mRNA | clofarabine | CTRPv2 | pan-cancer | AAC | 0.24 | 4e-15 |
| mRNA | LY-2183240 | CTRPv2 | pan-cancer | AAC | 0.22 | 8e-11 |
| mRNA | GSK461364 | CTRPv2 | pan-cancer | AAC | 0.22 | 1e-10 |
| mRNA | etoposide | CTRPv2 | pan-cancer | AAC | 0.2 | 4e-10 |
| mRNA | Topotecan | CTRPv2 | pan-cancer | AAC | 0.21 | 4e-10 |
| mRNA | carboplatin:etoposide (40:17 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.19 | 6e-10 |
| mRNA | ML311 | CTRPv2 | pan-cancer | AAC | 0.21 | 1e-09 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | 0.19 | 2e-09 |